MagnetisMM-7

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7)

More Information

Trial Status
Accepting patients
Trial Phase
Phase 3
Enrollment
760 patients (estimated)
Sponsors
Pfizer
Tags
Bispecific Antibody, GPRC5D
Trial Type
Treatment
Last Update
1 week ago
SparkCures ID
1322
NCT Identifier
NCT05317416

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.